Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
$0.00
$0.00
$0.00
N/AN/AN/A11,500 shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$232.56
+2.5%
$253.87
$161.65
$275.00
$11.98B1.4548,660 shs543,732 shs
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
$0.00
$0.00
$0.00
N/AN/A20,357 shsN/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
+2.55%-1.43%-14.68%+8.68%+15.76%
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
0.00%0.00%0.00%0.00%-90.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.5546 of 5 stars
2.34.00.04.73.12.52.5
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.64
Moderate Buy$253.238.89% Upside
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
N/AN/AN/AN/A

Current Analyst Ratings

Latest MEDD, BUX, BD1, and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$240.00 ➝ $290.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$260.00 ➝ $265.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$215.00 ➝ $250.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$270.00 ➝ $290.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$270.00 ➝ $280.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$252.00 ➝ $268.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.13B2.90$17.24 per share13.49$70.15 per share3.32
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$474.62M$9.2125.2518.801.7811.49%16.53%7.02%5/9/2024 (Confirmed)
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
N/A-$0.00N/AN/AN/AN/AN/AN/AN/A

Latest MEDD, BUX, BD1, and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.05N/A-$2.05N/AN/AN/A  
2/14/2024Q4 2023
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.39$2.46+$0.07$1.30$991.25 million$1.01 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.73
1.52
1.16
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
20.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/ANot Optionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
21,80051.51 million50.84 millionOptionable
Medical Imaging Corp. stock logo
MEDD
Medical Imaging
21N/AN/ANot Optionable

MEDD, BUX, BD1, and CRL Headlines

SourceHeadline
AIRS Medical Accelerates Global Expansion with MRI AI Solution SwiftMR™ Supply Contracts in Germany and the UKAIRS Medical Accelerates Global Expansion with MRI AI Solution SwiftMR™ Supply Contracts in Germany and the UK
prnewswire.co.uk - April 22 at 4:11 AM
Enhancing Patient Outcomes With Advanced Robotic SurgeonsEnhancing Patient Outcomes With Advanced Robotic Surgeons
medindia.net - April 21 at 11:43 AM
Medical AI pioneer VUNO sets sights on global frontierMedical AI pioneer VUNO sets sights on global frontier
msn.com - April 21 at 6:42 AM
Deleted Alien Franchise Scenes That Would Have Changed The MovieDeleted Alien Franchise Scenes That Would Have Changed The Movie
msn.com - April 20 at 5:32 PM
Urine Test Accurately Detected High-Grade Prostate CancerUrine Test Accurately Detected High-Grade Prostate Cancer
medpagetoday.com - April 18 at 5:59 PM
Global Teleradiology Services Market Set to Surge, Projected to Reach Over US$ 22,069.5 Million by 2033Global Teleradiology Services Market Set to Surge, Projected to Reach Over US$ 22,069.5 Million by 2033
fmiblog.com - April 18 at 7:59 AM
Huntsville Hospital to close wellness center at Medical Mall on July 1Huntsville Hospital to close wellness center at Medical Mall on July 1
waff.com - April 17 at 5:58 PM
Huntsville Hospital announces closure of one Wellness Center locationHuntsville Hospital announces closure of one Wellness Center location
msn.com - April 17 at 12:58 PM
FDA Approves Innovative 3D-Printed Cranial Implants for US Market EntryFDA Approves Innovative 3D-Printed Cranial Implants for US Market Entry
techtimes.com - April 17 at 7:58 AM
In a first, FDA approves 3D-printed cranial implants to enter USIn a first, FDA approves 3D-printed cranial implants to enter US
msn.com - April 16 at 3:55 PM
3D Systems achieves FDA 510(k) clearance for 3D printed PEEK cranial implant3D Systems achieves FDA 510(k) clearance for 3D printed PEEK cranial implant
tctmagazine.com - April 16 at 10:54 AM
3D Systems announces FDA clearance for 3D printed PEEK cranial implants3D Systems announces FDA clearance for 3D printed PEEK cranial implants
medicalplasticsnews.com - April 16 at 10:54 AM
The coming Pearl District already has a tenant — Charlotte’s first four-year med schoolThe coming Pearl District already has a tenant — Charlotte’s first four-year med school
msn.com - April 15 at 1:35 PM
FDA clears 3D-printed, patient-specific cranial implant from 3D SystemsFDA clears 3D-printed, patient-specific cranial implant from 3D Systems
massdevice.com - April 15 at 1:35 PM
How medtail merges health care with the convenience of retailHow medtail merges health care with the convenience of retail
bizjournals.com - April 12 at 3:58 PM
Rise in Chronic Diseases: Will Radiology Survive?Rise in Chronic Diseases: Will Radiology Survive?
emjreviews.com - April 11 at 11:26 PM
As much of commercial real estate in Twin Cities struggles, med-tech flourishesAs much of commercial real estate in Twin Cities struggles, med-tech flourishes
msn.com - April 11 at 8:25 AM
AtlantiCare’s transformative 6-year plan includes a med school, AI and high-profile partnershipsAtlantiCare’s transformative 6-year plan includes a med school, AI and high-profile partnerships
njbiz.com - April 11 at 8:25 AM
A biopsy without a scalpel — and moreA biopsy without a scalpel — and more
msn.com - April 10 at 8:25 PM
FFR-Guided Complete Revascularization Did Not Improve Outcomes in MI PatientsFFR-Guided Complete Revascularization Did Not Improve Outcomes in MI Patients
medpagetoday.com - April 10 at 3:25 PM
MedQuest Names Aalpen Patel Chief Clinical and Innovation OfficerMedQuest Names Aalpen Patel Chief Clinical and Innovation Officer
finance.yahoo.com - April 10 at 10:25 AM
Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)
medindia.net - April 8 at 9:24 AM
Cardiologys Bid to Defect From ABIM Plows AheadCardiology's Bid to Defect From ABIM Plows Ahead
medpagetoday.com - April 7 at 12:28 PM
Monteris Medical Announces Publication of Largest Cohort to Date of LITT with NeuroBlate® System for Meningioma, Most Common Primary Brain TumorMonteris Medical Announces Publication of Largest Cohort to Date of LITT with NeuroBlate® System for Meningioma, Most Common Primary Brain Tumor
medindia.net - April 4 at 10:28 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Biomark Diagnostics logo

Biomark Diagnostics

CNSX:BUX
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Charles River Laboratories International logo

Charles River Laboratories International

NYSE:CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Medical Imaging logo

Medical Imaging

OTCMKTS:MEDD
Medical Imaging Corp., through its subsidiaries, provides medical diagnostic imaging services for patients, hospitals and clinics, workers' compensation boards, and insurance companies in North America. It provides remote reading and reporting of medical diagnostic imaging scans. The company also provides magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound, nuclear medicine, digital mammography, X-ray, and bone mineral densitometry modalities. As of December 31, 2017, it operated an independent diagnostic imaging facility in Pottsville, Pennsylvania; and three diagnostic centers in Florida. The company was formerly known as Diagnostic Imaging International Corp. and changed its name to Medical Imaging Corp. in July 2014. Medical Imaging Corp. was incorporated in 2000 and is based in Las Vegas, Nevada.